Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.35 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2163434 | 1.00 | HCAR2 (0.41) | HCAR2ACHEBACE1CHRM1AKR1A1 | |
| SCHEMBL446905 | 0.88 | — | — | |
| SCHEMBL28445599 | 0.86 | TSHR (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5336276 | 0.85 | HCAR2 (0.53) | HCAR2ACHEBACE1CHRM1AKR1A1 | |
| SCHEMBL10396797 | 0.85 | HCAR2 (0.53) | HCAR2ACHEBACE1CHRM1AKR1A1 | |
| SCHEMBL11654063 | 0.85 | HCAR2 (0.53) | HCAR2ACHEBACE1CHRM1AKR1A1 | |
| Methoxymethane SCHEMBL3382894 | 0.84 | TSHR (0.39) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Succinic Acid SCHEMBL356090 | 0.82 | LMNA (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Ether SCHEMBL3377962 | 0.80 | TSHR (0.39) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3380945 | 0.78 | HSD17B10 (0.39) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211725-A1 | Pharmaceutical Composition Comprising Venetoclax | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2022-07-07 | — | — | US | claimed |
| WO-2020225738-A1 | PHARMACEUTICAL COMPOSITION COMPRISING VENETOCLAX | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2020-11-12 | — | — | WO | claimed |
| EP-1847257-B1 | Solid preparation comprising enteric solid dispersion | SHINETSU CHEMICAL CO (JP) | 2017-11-22 | — | — | EP | claimed |
| US-20140370091-A1 | Method for Producing Aqueous Enteric Coating Liquid, Solid Preparation, and Method for Producing Same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-12-18 | — | — | US | claimed |
| EP-2813218-A1 | Method for producing aqueous enteric coating liquid, solid preparation, and method for producing same | Shin-Etsu Chemical Co., Ltd. (JP) | 2014-12-17 | — | — | EP | claimed |
| US-20080038340-A1 | Solid dosage form of enteric solid dispersion and method for producing the same | SHIN-ETSU CHEMICAL CO., LTD. | 2008-02-14 | — | — | US | claimed |
| EP-1886673-A2 | Solid dosage form of enteric solid dispersion and method for producing the same | Shin-Etsu Chemical Co., Ltd. (JP) | 2008-02-13 | — | — | EP | claimed |
| US-20070248682-A1 | SOLID PREPARATION COMPRISING ENTERIC SOLID DISPERSION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | claimed |
| EP-1847257-A2 | Solid preparation comprising enteric solid dispersion | Shin-Etsu Chemical Co., Ltd. (JP) | 2007-10-24 | — | — | EP | claimed |
| US-20220211725-A1 | Pharmaceutical Composition Comprising Venetoclax | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2022-07-07 | — | — | US | disclosed |
| US-11292793-B2 | Solid dispersions of amorphous Lumateperone p-Tosylate | DR. REDDY'S LABORATORIES LIMITED (IN) | 2022-04-05 | — | — | US | disclosed |
| US-20210290541-A1 | SOLID DISPERSION OF HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-09-23 | — | — | US | disclosed |
| EP-3831381-A1 | SOLID DISPERSION OF HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020225738-A1 | PHARMACEUTICAL COMPOSITION COMPRISING VENETOCLAX | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2020-11-12 | — | — | WO | disclosed |
| US-20080038340-A1 | Solid dosage form of enteric solid dispersion and method for producing the same | SHIN-ETSU CHEMICAL CO., LTD. | 2008-02-14 | — | — | US | disclosed |
| EP-1886673-A2 | Solid dosage form of enteric solid dispersion and method for producing the same | Shin-Etsu Chemical Co., Ltd. (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20070248682-A1 | SOLID PREPARATION COMPRISING ENTERIC SOLID DISPERSION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1847257-A2 | Solid preparation comprising enteric solid dispersion | Shin-Etsu Chemical Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070196399-A1 | ENTERIC-COATED PREPARATION COVERED WITH ENTERIC COATING MATERIAL FOR SITE-SPECIFIC DELIVERY OF DRUG TO SITE WITHIN THE SMALL INTESTINE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1820498-A2 | Enteric-coated preparation for site-specific delivery of drug to site within the small intestine | Shin-Etsu Chemical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292793-B2 | Solid dispersions of amorphous Lumateperone p-Tosylate | HTR2A, HTR2C, HTR1A | HTR2A 1/4885HTR2C 2/4885ADRA1A 233/4885 |
| US-20210290541-A1 | SOLID DISPERSION OF HYDANTOIN DERIVATIVE | ABCG2, SEPTIN7, H1-0 | HTR2A 395/4885HTR2C 329/4885ADRA1A 1529/4885 |
| US-20220211725-A1 | Pharmaceutical Composition Comprising Venetoclax | U2AF1, SF3B1, SF3B3 | HTR2A 4820/4885HTR2C 4612/4885ADRA1A 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.